Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried?
11:16am, Tuesday, 05'th Mar 2024
Viking Therapeutics' weight loss candidate produced positive phase 2 results. The drug could eventually be a challenger to Novo Nordisk's Wegovy.
Novo Nordisk reveals positive Ozempic kidney results
10:47am, Tuesday, 05'th Mar 2024
Novo Nordisk (NYSE:NVO) said diabetes patients have been able to prevent the onset of chronic kidney disease in trials of semaglutide, which it sells under the Ozempic and Wegovy brands. The Danish d
Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why
09:53am, Tuesday, 05'th Mar 2024
Eli Lilly and Novo Nordisk stock each rose over 50% in 2023 thanks to their diabetes treatments. Industry research suggests the diabetes market will continue to grow for decades to come.
Novo Nordisk's diabetes drug Ozempic slashed the risk of kidney disease progression in trial
08:47am, Tuesday, 05'th Mar 2024
The results add to the growing evidence that the highly popular injection has broader health benefits for patients beyond treating Type 2 diabetes.
Novo Nordisk shares falls after diabetic kidney results reported
07:23am, Tuesday, 05'th Mar 2024
Novo Nordisk (NYSE:NVO) said diabetes patients have been able to prevent the onset of chronic kidney disease in trials of semaglutide, which it sells under the Ozempic and Wegovy brands. The Danish d
Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making
06:28am, Tuesday, 05'th Mar 2024
The world of biotech stocks offers a unique blend of high risk and potentially high reward. Companies operating in this space are constantly pushing the boundaries, making them primed investment oppor
Novo Nordisk Ozempic trial delays progression of chronic kidney disease
05:07am, Tuesday, 05'th Mar 2024
Novo Nordisk's widely used diabetes drug Ozempic delayed progression of chronic kidney disease in diabetes patients, according to a large late-stage study.
The Ozempic Diet Trend is Lifting These 2 Carnivore Stocks
06:28am, Monday, 04'th Mar 2024
At $1,300 a month, with limited supply, and side effects including nausea, vomiting and gastrointestinal maladies, there are plenty of reasons to find more cost-effective and appetizing ways to lose w
Better Blockbuster-Drug Stock: Novo Nordisk vs. Eli Lilly
12:51pm, Sunday, 03'rd Mar 2024
Blockbuster drugs can be disproportionately beneficial for biopharmas. Novo Nordisk is already squeezing a lot of cash out of semaglutide.
Missed Out on Novo Nordisk Stock? Buy This 1 Biotech Stock Right Now.
07:41am, Sunday, 03'rd Mar 2024
Viking Therapeutics wowed the market with its latest phase 2 data. Its weight loss drug candidate might be better than the competition.
Can we cut Oprah Winfrey some slack? The struggle to lose weight is real — and drugs can be a lifesaver.
08:18am, Saturday, 02'nd Mar 2024
Yes, Oprah Winfrey is in the news again — in this case, for her decision to sell her stake in WW International WW, +8.33% (formerly known as WeightWatchers) and leave the company's board. The decisi
Why Novo Nordisk Stock Topped the Market Today
06:15pm, Friday, 01'st Mar 2024
An analyst cranked his price target higher on the Danish pharmaceutical company. He increased it by 16%.
These 4 Stocks Are the "Magnificent Seven" of Healthcare
01:59am, Friday, 01'st Mar 2024
The Magnificent Seven are stealing the show this year on the market. They're all technology companies -- but there are opportunities elsewhere, too.
Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared Holz
01:40pm, Thursday, 29'th Feb 2024
CNBC's Melissa Lee and Jared Holz, Mizuho Securities America healthcare sector strategist, join 'Squawk on Street' to discuss the weight-loss drug market, why he believes Eli Lilly and Novo Nordisk wi
What Would George Soros Do? 7 Stocks the Billionaire's Fund Bought & Sold in Q4
11:39am, Wednesday, 28'th Feb 2024
George Soros stocks will always remain relevant for savvy investors. As one of the most successful financiers in history, George Soros's investment strategies attract a massive audience worldwide.
